Nexalin Technology Inc Revenue Growth Rates (NXL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nexalin Technology Inc   (NASDAQ: NXL)
 

NXL's Revenue Growth by Quarter and Year

Nexalin Technology Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NXL/growth
https://api.csimarket.com/api/v1/companies/NXL/fundamentals
https://api.csimarket.com/api/v1/companies/NXL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NXL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.08
2nd Quarter June 0.01
1st Quarter March 0.01
FY 0.10





NXL Revenue third quarter 2026 Y/Y Growth Comment
Nexalin Technology Inc achieved in the third quarter 2026, above Company average Revenue surge of 291.5% year on year, to $ 0.08 millions.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 182 other companies have achieved higher Revenue growth. While Nexalin Technology Inc ' s Revenue doubling of 291.5% ranks overall at the positon no. 3892 in the third quarter 2026.


NXL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 291.5 %
2nd Quarter June -85.71 %
1st Quarter March -75 %
FY   -

Financial Statements
Nexalin Technology Inc 's third quarter 2026 Revenue $ 0.08 millions NXL's Income Statement
Nexalin Technology Inc 's third quarter 2025 Revenue $ 0.02 millions Quarterly NXL's Income Statement


NXL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 683.01 %
2nd Quarter June 0 %
1st Quarter March -94.12 %
FY (Year on Year)   -


Back to NXL Growth rate Comparisons >> Back to NXL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #183
Healthcare Sector #556
Overall #3892

Revenue Y/Y Growth Statistics
High Average Low
873.79 % 72.47 % -95.58 %
(Mar 31 2026)   (Dec 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #183
Healthcare Sector #556
Overall #3892
Revenue Y/Y Growth Statistics
High Average Low
873.79 % 72.47 % -95.58 %
(Mar 31 2026)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nexalin Technology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
847.13 % 65.92 % -92.95 %
(Dec 31 2025)  


NXL's III. Quarter Q/Q Revenue Comment
Nexalin Technology Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 683.01%, to $ 0.08 millions, from $0.01 millions in the second quarter.
NXL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 185 other companies have achieved higher Revenue quarter on quarter growth. While Nexalin Technology Inc 's Revenue growth quarter on quarter, overall rank is 3885.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #186
Healthcare Sector #583
Overall #3885
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #186
Healthcare Sector #583
Overall #3885
Revenue Q/Q Growth Statistics
High Average Low
847.13 % 65.92 % -92.95 %
(Dec 31 2025)  


NXL's III. Quarter Q/Q Revenue Comment
Nexalin Technology Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 683.01%, to $ 0.08 millions, from $0.01 millions in the second quarter.
NXL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 185 other companies have achieved higher Revenue quarter on quarter growth. While Nexalin Technology Inc 's Revenue growth quarter on quarter, overall rank is 3885.


Nexalin Technology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 0.28
Y / Y Revenue Growth (TTM) 76.71 %
Year on Year Revenue Growth Overall Ranking # 1037
Seqeuential Revenue Change (TTM) 27.7 %
Seq. Revenue Growth (TTM) Overall Ranking # 508


Cumulative Revenue growth Comment
Nexalin Technology Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 76.71% year on year, to $ 0 millions if the fiscal year would have ended in Sep 30 2026.
Nexalin Technology Inc 's trailing twelve months Revenue growth was higher than company's average -6.35% and higher than 24.22% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 27.7 % from $0.22 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -6.35%.

In the Healthcare sector 196 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 69 to 1037.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 31
Healthcare Sector # 197
Overall # 1037

Revenue TTM Y/Y Growth Statistics
High Average Low
110.26 %
 -6.35 %
-91.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 31
Sector # 120
S&P 500 # 508
Cumulative Revenue growth Comment
Nexalin Technology Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 76.71% year on year, to $ 0 millions if the fiscal year would have ended in Sep 30 2026.
Nexalin Technology Inc 's trailing twelve months Revenue growth was higher than company's average -6.35% and higher than 24.22% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 27.7 % from $0.22 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -6.35%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 27.7 % increase from $0.22 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 196 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 69 to 1037.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 31
Healthcare Sector # 197
Overall # 1037

Revenue TTM Y/Y Growth Statistics
High Average Low
110.26 %
-6.35 %
-91.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 31
Sector # 120
S&P 500 # 508




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NXL's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Bio Green Med Solution Inc 460.49%$ 460.494 millions
Xencor Inc454.88%$ 454.884 millions
Tonix Pharmaceuticals Holding Corp 423.83%$ 423.830 millions
Nakamoto Inc 396.90%$ 396.897 millions
EBR Systems, Inc.385.65%$ 385.647 millions
Solana Company382.07%$ 382.066 millions
Pulse Biosciences Inc 359.30%$ 359.302 millions
Ensysce Biosciences Inc 342.43%$ 342.428 millions
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions


About Nexalin Technology Inc Revenue Growth Rates (NXL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nexalin Technology Inc (CIK 1527352).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001829126-26-012319
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nexalin Technology Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.